Imbruvica (ibrutinib)

pCPA File Number: 22489

Negotiation Status:

Active Negotiation

Indication(s):

Chronic lymphocytic leukemia (CLL), in adult patients with previously untreated CLL, including those with 17p deletion

Sponsor/Manufacturer:

Janssen Inc.

CDA-AMC Project Number:

PC0317-000

pCPA Engagement Letter Issued:

2024-10-03

Negotiation Process Concluded:

Not Applicable